- Home
- AGEN vs VERI Comparison
AGEN vs VERI Comparison
Compare AGEN & VERI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- VERI
- Stock Information
- Founded
- AGEN 1994
- VERI 2014
- Country
- AGEN United States
- VERI United States
- Employees
- AGEN N/A
- VERI N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- VERI EDP Services
- Sector
- AGEN Health Care
- VERI Technology
- Exchange
- AGEN Nasdaq
- VERI Nasdaq
- Market Cap
- AGEN 87.7M
- VERI 91.5M
- IPO Year
- AGEN 2000
- VERI 2017
- Fundamental
- Price
- AGEN $5.09
- VERI $1.54
- Analyst Decision
- AGEN Buy
- VERI Strong Buy
- Analyst Count
- AGEN 4
- VERI 3
- Target Price
- AGEN $13.00
- VERI $4.17
- AVG Volume (30 Days)
- AGEN 1.6M
- VERI 652.6K
- Earning Date
- AGEN 08-07-2025
- VERI 08-07-2025
- Dividend Yield
- AGEN N/A
- VERI N/A
- EPS Growth
- AGEN N/A
- VERI N/A
- EPS
- AGEN N/A
- VERI N/A
- Revenue
- AGEN $99,524,000.00
- VERI $90,947,000.00
- Revenue This Year
- AGEN $14.49
- VERI $15.84
- Revenue Next Year
- AGEN N/A
- VERI $22.96
- P/E Ratio
- AGEN N/A
- VERI N/A
- Revenue Growth
- AGEN N/A
- VERI N/A
- 52 Week Low
- AGEN $1.38
- VERI $1.42
- 52 Week High
- AGEN $18.74
- VERI $5.64
- Technical
- Relative Strength Index (RSI)
- AGEN 62.39
- VERI 37.91
- Support Level
- AGEN $5.06
- VERI $1.50
- Resistance Level
- AGEN $6.35
- VERI $1.62
- Average True Range (ATR)
- AGEN 0.59
- VERI 0.10
- MACD
- AGEN 0.12
- VERI 0.01
- Stochastic Oscillator
- AGEN 65.00
- VERI 30.77
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About VERI Veritone Inc.
Veritone Inc is a provider of artificial intelligence (AI) computing solutions and services. It generates revenue through the delivery of its Software Products and Services which consists of revenues generated from Commercial Enterprise and Government and Regulated Industries customers using the company's aiWARE platform and hiring solutions, any related support and maintenance services, and any related professional services associated with the deployment and/or implementation of such solutions, Managed Services which consist of revenues generated from Commercial Enterprise customers using company's content licensing services, advertising agency, influencer management and related services. It has a presence in the United States, the United Kingdom, France, Australia, Israel, and India.